Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Neurology and Neurosurgery
  • Neurology & Neurosurgery News
  • Atogepant- new...

Atogepant- new solution for migraines

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-06-17T09:15:23+05:30  |  Updated On 17 Jun 2022 3:22 PM IST
Atogepant- new solution for migraines
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: In a new article published in the Journal of American Medical Association, atogepant was shown to be effective and well-tolerated for the preventive treatment of migraine. This was evident by a significant reduction in the average monthly migraine day (MMD) at each response threshold.

Patients with migraine, especially those in primary care, require effective and tolerable migraine-specific oral prophylaxis. Therefore, this study was conducted by Richard B. Spencer and his team, using a four-level mean MMD response to an oral, small molecule, calcitonin gene-related peptide receptor antagonist, Atogepant, and evaluated the effectiveness of-Investigate rates.

A secondary analysis of this Phase 3 placebo-controlled, double-blind, randomized clinical trial found migraine prevention in adults aged 4 to 14 years from December 14, 2018, to June 19, 2020. We evaluated the efficacy and safety of Atogepant for clinical trials. The number of days of migraine per month is 128 locations in the United States. Patients should take Atogepant10 mg (n = 222), Atogepant 30 mg (n = 230), Atogepant 60 mg (n = 235), or placebo (n = 223) once daily, 1: 1: 1: 1. It was administered 12 times at the ratio of. several weeks. In these analyses, participants achieved an average MMD reduction of 50% or greater (secondary endpoint of alpha control) and 25% or greater, 75% or greater, and 100% (additional pre-specified endpoint). The treatment response rate defined was evaluated. On average, MMD under treatment reached a 12-week blinded treatment period.

The key findings of this study were as follows:

1. Of the 902 participants, 873 joined the modified ITT population. As for secondary endpoints, 119 of 214 (55.6%) treated with Atogepant 10 mg and 131 of 223 (58.7%) treated withAtogepant 30 mg experienced a 12-week reduction.

2. Did-Average MMD achieved over 50%. 135 of 222 subjects (60.8%) were treated with Atogepant 60 mg and 62 of 214 (29.0%) received a placebo.

3. The number of participants who reported a 25% or greater reduction in mean 12-week MMD was 157/214 (73.4%) with 10 mg of Atogepant, 172/223 (77.1%) with 30 mg Atogepant, and 180 of 222 (2). It was 81.1%).

4. In the case of Atogepant 60 mg, 126 (58.9%) of 214 in the case of placebo. The number of participants who reported a 75% or greater reduction in mean MMD was 65/214 (30.4%) with Atogepant 10 mg, 66/223 (29.6%), and 84/222 (37.8%) with Atogepant 30 mg.

5. With 60 mg of Atogepant compared to 23/214 (10.7%) of placebo. The number of participants who reported a 100% reduction in mean MMD was 17/214 (7.9%) with Atogepant 10 mg, 11/223 (4.9%) with Atogepant 30 mg, and 17/222 (7.7%) with Atogepant 60 Mg Atogepant compared to 2/214 (0.9%) of placebo.

"Atogepant appears to be effective and well-tolerated for the preventive treatment of migraine as measured by 4 levels of the clinically meaningful end point of responder rates," the authors wrote.

They concluded, "higher doses of atogepant appear to produce the maximum response rate, which may help physicians customize the starting dose.

Reference:

Lipton, R. B., Pozo-Rosich, P., Blumenfeld, A. M., Dodick, D. W., McAllister, P., Li, Y., Lu, K., Dabruzzo, B., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2022). Rates of Response to Atogepant for Migraine Prophylaxis Among Adults. In JAMA Network Open (Vol. 5, Issue 6, p. e2215499). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2022.15499

JAMA Network Openmigraineatogepantpainkiller
Source : JAMA Network Open
Jacinthlyn Sylvia
Jacinthlyn Sylvia

    Neuroscience Masters graduate

    Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    View All

    Journal Club Today

    Intensive Blood Pressure Control Reduces Dementia Risk: Study Finds

    Intensive Blood Pressure Control Reduces Dementia Risk: Study Finds

    View All

    Health News Today

    Health Bulletin 02/June/2025

    Health Bulletin 02/June/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok